Veterans with diabetes can now consider SGLT2 inhibitors without the concern of heightened fracture risk, according to a recent comprehensive study. This investigation compared fracture incidences between those using SGLT2 inhibitors and those on DPP4 inhibitors, providing valuable insights for treatment strategies.
Robust Data Analysis Ensures Reliable Results
Researchers compiled data from Veterans Administration, Medicare, and the National Death Index databases, focusing on new users of SGLT2 inhibitors versus DPP4 inhibitors. The study meticulously followed patients from their initial prescription until a fracture occurred, death, discontinuation of medication, loss to follow-up, or the study’s conclusion. Fracture types included areas such as the spine, ribs, long bones, and hips, identified using a highly accurate algorithm with a positive predictive value of over 91%.
Comparable Fracture Rates Highlight Safety of SGLT2i
The analysis encompassed over 115,000 SGLT2 inhibitor episodes and over 213,000 DPP4 inhibitor episodes, with a median patient age of nearly 70 years and an average diabetes duration of nearly a decade. After adjusting for numerous variables, including comorbidities and medication types, the fracture rates between the two groups remained statistically similar. Specifically, the adjusted hazard ratio indicated no increased risk of fractures among SGLT2 inhibitor users compared to those on DPP4 inhibitors.
- SGLT2 inhibitors were predominantly empagliflozin, followed by canagliflozin and dapagliflozin.
- DPP4 inhibitor usage included saxagliptin, sitagliptin, alogliptin, and linagliptin.
- The study balanced over 70 covariates to ensure accurate comparisons.
- Fracture incidence per 1000 person-years showed no significant difference between groups.
The findings provide reassurance regarding the skeletal safety of SGLT2 inhibitors when used as an add-on therapy for diabetes management in veterans. This is particularly important given the concerns about bone metabolism in diabetic patients receiving these medications.
Healthcare providers can confidently prescribe SGLT2 inhibitors without the added worry of increasing fracture risk, allowing for more flexible and effective diabetes treatment plans. Future research may further explore long-term outcomes and specific patient subgroups to continue enhancing diabetes care protocols.
With diabetes being a prevalent condition among veterans, ensuring that treatment options do not exacerbate other health risks is crucial. This study contributes significantly to the understanding of SGLT2 inhibitors’ safety profile, potentially influencing guidelines and patient care practices.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
